Replies to post #36378 on OncoSec Medical Inc (ONCSQ)

[trading.jeff]

Lung cancer (NSCLC) would be a great start for this device, IMO. It's the most prevalent and lethal of all cancers.

Somewhere, I had the impression that melanoma was the most prevalent of cancers.

$ONCS

[hschlauch]

I tend to think melanoma is a low hanging fruit for electroporation. Device improvements would need to be made to reach visceral tumors. Proof of principle in applying EP IL-12 with other potential gene combinations in deeper tissues and organs needs to be addressed before anyone can become confident in indications outside melanoma. We have not seen any data yet, not even on a preclinical level, for applications in visceral tumors. I think the company needs to demonstrate that electroporation can work in these other disease indications.

If the current phase 2 combination melanoma trial demonstrates success in the non-responder population AND they can demonstrate success in getting to deeper solid tumors, then the sky is the limit in terms of treatment opportunity with checkpoint inhibitors. I am obviously very curious how successful they can be in electroporating deeper solid tumors.